February 5, 2019 / 4:30 PM / 8 months ago

BRIEF-Xencor To Develop, Commercialize Il-15 Immune Activating Cytokines With Roche's Genentech

Feb 5 (Reuters) - Xencor Inc:

* XENCOR TO DEVELOP AND COMMERCIALIZE NOVEL IL-15 IMMUNE ACTIVATING CYTOKINES WITH GENENTECH

* XENCOR INC - ENTERED INTO A RESEARCH AND LICENSE AGREEMENT WITH GENENTECH

* XENCOR INC - UNDER TERMS OF AGREEMENT, COMPANIES WILL CO-DEVELOP XMAB24306 AND OTHER POTENTIAL IL-15 PROGRAMS

* XENCOR INC - GENENTECH WILL PAY XENCOR $120 MILLION UPFRONT

* XENCOR INC - ALSO XENCOR WILL BE ELIGIBLE TO RECEIVE UP TO $160 MILLION IN DEVELOPMENT MILESTONES FOR XMAB24306 PROGRAM

* XENCOR INC - ALSO XENCOR WILL BE ELIGIBLE TO RECEIVE UP TO $180 MILLION IN DEVELOPMENT MILESTONES FOR EACH NEW IL-15 DRUG CANDIDATE

* XENCOR INC - GENENTECH WILL COMMERCIALIZE MEDICINES WORLDWIDE, AND XENCOR HAS OPTION TO CO-PROMOTE IN UNITED STATES

* XENCOR INC - COMPANIES WILL ENGAGE IN A TWO-YEAR RESEARCH PROGRAM TO DISCOVER NEW IL-15 DRUG CANDIDATES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below